This includes best-in-class reimbursement and market access capabilities that can be leveraged to accelerate Alcon’s growth around the world, such as enhanced market access for advanced technology IOL ...

Alcon is a global leader in IOLs and controls 40%-50% of the market, by our estimate. Its AcrySof IQ IOL, which was launched in 1994, is most implanted IOL in the world. It was the first IOL to be ...

Alcon is a global leader in IOLs and controls 40%-50% of the market, by our estimate. Its AcrySof IQ IOL, which was launched in 1994, has been implanted in more than 135 million eyes, making it ...

The new 74,000-square-foot building will be fully functional by 2011 and will allow Alcon's Huntington area operations to remain the world's largest intraocular lens (IOL) manufacturing site. Once ...

Alcon's new eye drop is designed to alleviate symptoms caused by aging, environmental factors, and digital device use, with a US launch and global expansion planned by 2026. Alcon announced the US ...

The survey of US doctors suggests strong intraocular lens (IOL) volumes, and Alcon's PanOptix Pro launch is expected to help the company recapture market share lost to competitors like Johnson ...

The device is available in select markets, broadening access to first-line SLT therapy and expanding Alcon's glaucoma treatment portfolio. The new first-line laser treatment for glaucoma and ocular ...